EirGenix, Inc. 6589

As the global biopharmaceutical industry undergoes rapid restructuring, two powerful forces—policy evolution and supply chain transformation—are reshaping Japan's landscape. On one side, the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) have built a solid regulatory framework to accelerate biosimilar development. On the other hand, geopolitical risks and economic policy shifts are driving a stronger focus on domestic production capacity a

PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and

On November 12, 2025, EirGenix Inc. announced a global license agreement granting Sandoz Group exclusive worldwide commercial rights (excluding select Asian markets) to a proposed biosimilar of oncology medicine pertuzumab, with a total consideration of up to US$152 million based on milestones and future market performance. This collaboration expands Sandoz’s oncology biosimilar pipeline and strengthens its partnership with EirGenix, reinforcing Sandoz’s ambitions in a biosimilar market...